MedPageToday -- SAN ANTONIO -- Signs of liver toxicity do not appear increased with the use of infliximab (Remicade) in rare cases where an inflammatory bowel disease (IBD) patient also has chronic hepatitis C virus (HCV) infection, researchers said here.
